JP2002542169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542169A5 JP2002542169A5 JP2000611685A JP2000611685A JP2002542169A5 JP 2002542169 A5 JP2002542169 A5 JP 2002542169A5 JP 2000611685 A JP2000611685 A JP 2000611685A JP 2000611685 A JP2000611685 A JP 2000611685A JP 2002542169 A5 JP2002542169 A5 JP 2002542169A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- toxin
- fragment
- recombinant
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 50
- 230000002163 immunogen Effects 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 21
- 239000012634 fragment Substances 0.000 description 20
- 235000004252 protein component Nutrition 0.000 description 20
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 16
- 101710182532 Toxin a Proteins 0.000 description 16
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 101710182223 Toxin B Proteins 0.000 description 11
- 230000028993 immune response Effects 0.000 description 10
- 241000193163 Clostridioides difficile Species 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000193985 Streptococcus agalactiae Species 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 108700022831 Clostridium difficile toxB Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 230000004665 defense response Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12868699P | 1999-04-09 | 1999-04-09 | |
| US60/128,686 | 1999-04-09 | ||
| US18620100P | 2000-03-01 | 2000-03-01 | |
| US60/186,201 | 2000-03-01 | ||
| US19011100P | 2000-03-20 | 2000-03-20 | |
| US60/190,111 | 2000-03-20 | ||
| PCT/US2000/009525 WO2000061762A1 (en) | 1999-04-09 | 2000-04-10 | RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009298925A Division JP5566684B2 (ja) | 1999-04-09 | 2009-12-28 | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002542169A JP2002542169A (ja) | 2002-12-10 |
| JP2002542169A5 true JP2002542169A5 (enExample) | 2006-08-31 |
Family
ID=27383767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000611685A Pending JP2002542169A (ja) | 1999-04-09 | 2000-04-10 | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| JP2009298925A Expired - Fee Related JP5566684B2 (ja) | 1999-04-09 | 2009-12-28 | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009298925A Expired - Fee Related JP5566684B2 (ja) | 1999-04-09 | 2009-12-28 | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP2502998A3 (enExample) |
| JP (2) | JP2002542169A (enExample) |
| AU (1) | AU781175B2 (enExample) |
| CA (1) | CA2365915C (enExample) |
| WO (1) | WO2000061762A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205206D0 (en) * | 2002-03-06 | 2002-04-17 | Oxoid Ltd | Synthetic peptides |
| US6912151B2 (en) | 2002-06-28 | 2005-06-28 | Synopsys, Inc. | Negative differential resistance (NDR) based memory device with reduced body effects |
| JP2012510497A (ja) * | 2008-12-03 | 2012-05-10 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ワクチンの生産方法 |
| EP3167899B1 (en) | 2010-09-03 | 2021-03-24 | Valneva Austria GmbH | Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof |
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| MX391236B (es) | 2011-04-22 | 2025-03-21 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. |
| AU2016203241B2 (en) * | 2011-05-27 | 2018-05-10 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| EP3564378B1 (en) | 2011-05-27 | 2023-11-01 | GlaxoSmithKline Biologicals SA | Immunogenic composition |
| SG11201402375VA (en) | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| GB201206070D0 (en) * | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| AU2013354186A1 (en) | 2012-12-05 | 2014-06-12 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| JP2016501550A (ja) | 2012-12-27 | 2016-01-21 | グリコヴァキシン アーゲー | Ｃｒｍ１９７に関する方法及び組成物 |
| SI3160500T1 (sl) * | 2014-06-25 | 2019-11-29 | Glaxosmithkline Biologicals Sa | Imunogeni sestavek proti Clostridium difficile |
| ES2870506T3 (es) | 2015-02-19 | 2021-10-27 | Immune Biosolutions Inc | Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos |
| EP3810163A1 (en) | 2018-06-19 | 2021-04-28 | GlaxoSmithKline Biologicals SA | Immunogenic composition |
| EP3880240A4 (en) * | 2018-11-16 | 2022-08-03 | Matrivax, Inc. | Clostridium difficile multi-component vaccine |
| CN112442472B (zh) * | 2020-11-30 | 2023-05-26 | 四川大学华西医院 | 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法 |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| WO2024160901A1 (en) | 2023-02-02 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4530833A (en) | 1982-09-13 | 1985-07-23 | Wilkins Tracy D | Toxins and antibodies of C. difficile |
| US4533630A (en) | 1982-09-13 | 1985-08-06 | Wilkins Tracy D | Toxins and antibodies of C. difficile |
| US4879218A (en) | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US4863852A (en) | 1985-07-03 | 1989-09-05 | Virginia Tech Intellectual Properties, Inc. | Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors |
| GB8517071D0 (en) * | 1985-07-05 | 1985-08-14 | Hoffmann La Roche | Gram-positive expression control sequence |
| US5736139A (en) | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| US5098826A (en) | 1990-03-09 | 1992-03-24 | Virginia Tech Intellectual Properties, Inc. | Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors |
| WO1993006217A1 (en) * | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| DE69535530D1 (de) * | 1994-10-24 | 2007-08-16 | Ophidian Pharm Inc | Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten |
| ATE195878T1 (de) * | 1995-07-07 | 2000-09-15 | Oravax Inc | Toxine und toxoide von clostridium difficile als schleimhautadjuvans |
| US5919463A (en) | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
| JPH09323999A (ja) * | 1996-06-03 | 1997-12-16 | Unitika Ltd | 人工タンパク質ポリマー |
| AU746859B2 (en) * | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
| EP3167899B1 (en) * | 2010-09-03 | 2021-03-24 | Valneva Austria GmbH | Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof |
-
2000
- 2000-04-10 WO PCT/US2000/009525 patent/WO2000061762A1/en not_active Ceased
- 2000-04-10 JP JP2000611685A patent/JP2002542169A/ja active Pending
- 2000-04-10 EP EP12155470A patent/EP2502998A3/en not_active Withdrawn
- 2000-04-10 EP EP00931926A patent/EP1169456B1/en not_active Expired - Lifetime
- 2000-04-10 AU AU49732/00A patent/AU781175B2/en not_active Ceased
- 2000-04-10 CA CA2365915A patent/CA2365915C/en not_active Expired - Fee Related
-
2009
- 2009-12-28 JP JP2009298925A patent/JP5566684B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002542169A5 (enExample) | ||
| KR100500782B1 (ko) | 융합단백질로서의 이종성 항원유전자 발현 시스템 | |
| JP3267333B2 (ja) | 融合タンパク質 | |
| JP5566684B2 (ja) | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン | |
| US9346860B2 (en) | Expression system | |
| JP2764022B2 (ja) | 免疫グロブリン結合性タンパク質及びその製造方法 | |
| EP3099800B1 (en) | Expression and purification of crm197 and related proteins | |
| Belev et al. | A fully modular vector system for the optimization of gene expression in Escherichia coli | |
| US4985243A (en) | Composition and method for protecting against diseases caused by microorganisms | |
| EA006232B1 (ru) | Стрептококковые антигены | |
| EP0746621A1 (en) | Expression of proteins on bacterial surface | |
| JP2005097321A (ja) | 緑膿菌膜タンパク質由来免疫原性ハイブリッドＯｐｒＦ−ＯｐｒＩ | |
| Rezaei et al. | Production of Brucella melitensis Omp16 protein fused to the human interleukin 2 in Lactococcus lactis MG1363 toward developing a Lactococcus-based vaccine against brucellosis | |
| JP2023154063A (ja) | 肺炎球菌表面タンパク質Ａ（ＰｓｐＡ）の発現 | |
| Abomoelak et al. | Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guerin producing a pertussis toxin-tetanus toxin hybrid protein | |
| HUT64596A (en) | Recombinant vaccine against swine pleuropneumonie | |
| CN101948546B (zh) | 融合蛋白SAmB及其编码基因与应用 | |
| US6777202B2 (en) | Recombinant expression of S-layer proteins | |
| CN100427506C (zh) | 从融合多肽制备感兴趣的多肽的方法 | |
| US20030165526A1 (en) | Vaccines and agents for inducing immunity against rickettsial diseases, and associated preventative therapy | |
| JPH08512210A (ja) | ペプチドの合成及び精製のための方法 | |
| JP7161729B2 (ja) | 多価ワクチン | |
| KR102280493B1 (ko) | GnRH가 삽입된 STF2 재조합 단백질 및 이의 용도 | |
| WO1996026282A1 (en) | Expression of gene products from genetically manipulated strains of bordetella | |
| EP0087735A2 (en) | Recombinant DNA, microorganism transformed therewith and their use |